Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation

Joeres, S.; Heussen, Florian M.; Treziak, Tobias; Bopp, Silvia; Joussen, Antonia M.

doi:10.1007/s00417-007-0580-y

Cited by 58 publications

(40 citation statements)

References 22 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[34][35][36] The first encouraging results in the treatment of serous PED were found with pegaptanib, followed by bevacizumab and ranibizumab. [37][38][39][40] However, these initial reports comprised only small numbers of treated patients. In our larger case series, we found a significant stabilization of VA over a period of 24 weeks after treatment.…”

Section: Discussionmentioning

confidence: 99%

Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments

Lommatzsch

Heimes

Gutfleisch

et al. 2009

Eye

View full text Add to dashboard Cite

Aims To investigate the therapeutic effects of different treatments on serous pigment epithelium detachment (PED) in age-related macular degeneration (AMD). Methods A total of 328 patients suffering from serous PED in AMD were retrospectively analysed. We treated only patients with documented visual deterioration: 86 patients with bevacizumab, 128 with ranibizumab, 60 with pegaptanib, and 54 with photodynamic therapy (PDT) combined with intravitreal triamcinolone acetonide (IVTA). Bestcorrected vision was determined in the logarithm of the minimal angle of resolution (logMAR). We also analysed morphological findings such as full foveal thickness by optical coherence tomography (OCT), manually calculated height of PED as measured by OCT, and fluorescence angiography. Results The mean follow-up was 42.4 weeks. The best-corrected visual acuity of 0.78 logMAR before treatment could be improved by about 0.066 logMAR after treatment. Retinal thickness decreased in all patients with PED, in the mean by about 64.06 lm, and the mean value of the manually calculated height decreased by about 0.98 units. All functional and morphological results proved to be significantly better after injection of ranibizumab and bevacizumab than after pegaptanib and the combined treatment with PDT and IVTA. In all, 41 (12.5%) of our patients developed a tear of the retinal pigment epithelium (RPE). Conclusion The therapeutic results were significantly better in patients treated with bevacizumab and ranibizumab than in those treated with pegaptanib or with a combination of PDT and IVTA. Even with treatment, tears of the RPE or only a partial flattening of the PED always indicated a worse prognosis in eyes with exudative AMD than in eyes with classic choroidal neovascularization.

show abstract

Section: Discussionmentioning

confidence: 99%

Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments

Lommatzsch

Heimes

Gutfleisch

et al. 2009

Eye

View full text Add to dashboard Cite

show abstract

“…Only with introduction of anti-vascular endothelial growth factor drugs (VEGF) the results are slightly more promising, both with Bevacizumab (Avastin ® ) [21][22][23] and Ranibizumab (Lucentis ® ) [24]. Still, RAP seems to be an aggressive form of neovascularization.…”

Section: Introductionmentioning

confidence: 99%

Late Stage III Retinal Angiomatous Proliferation with Retino-Choroidal Anastomosis do not Respond Well to Treatment with Ranibizumab (Lucentis®)

Matthé¹,

Sandner²,

Maaß³

2017

Int J Neurorehabilitation Eng

View full text Add to dashboard Cite

Background: Retinal Angiomatous Proliferations (RAP) is a subgroup of exsudative or "wet" Age-related Macular Degeneration (wAMD) with devastating reduction of visual acuity in later stages. Intravitreal Ranibizumab provides a good therapy, but is considered to be not as effective in this class of neovascularization compared to choroidal neovascularization (CNV). We investigated the efficacy of Ranibizumab in late stage III RAP with retino-choroidal anastomosis compared to the outcome of CNV lesions.

show abstract

“…2 Two case series have shown promising 3 month data on treatment of RAP with intravitreal bevacizumab. 21,22 At the time of writing, there are no published reports of the effectiveness of ranibizumab or pegaptanib in the treatment of RAP. We report 6-month follow-up of a case series of patients with RAP treated with intravitreal pegaptanib.…”

Section: Introductionmentioning

confidence: 99%

Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review

Mahmood

Kumar

Lenfestey

et al. 2008

Eye

View full text Add to dashboard Cite

Aims To evaluate the early functional and anatomical responses to intravitreal pegaptanib in patients with retinal angiomatous proliferation (RAP). Methods Retrospective review of consecutive patients newly diagnosed with RAP treated with intravitreal pegaptanib (0.3 mg). Examination at baseline and 12 weekly intervals included refraction protocol best corrected visual acuity (BCVA), fluorescein angiography (FA), and optical coherence tomography (OCT). At intervening 6 weekly visits a reduced protocol assessment included BCVA and OCT. Results A total of 16 eyes of 16 patients (12 female, mean age 76.0 years) with RAP at baseline (15 stage 3, one stage 2) were treated. One patient had poor response, losing 20 ETDRS letters after one injection and was switched to photodynamic therapy combined with intravitreal triamcinolone. Mean BCVA (n ¼ 15) was baseline 45±11 (mean±SD) letters, 12 weeks 43±14 letters, 24 weeks 40 ± 14 letters; the reduction from baseline to 24 weeks was statistically significant (P ¼ 0.04). Vision remained stable defined as ± 15 letters of baseline BCVA in 13 (87%) of patients 2 (13%) lost 415 letters. Mean OCT central foveal thickness (CFT) (n ¼ 13) was: baseline 325±123 lm, 12 weeks 343±130 lm, 24 weeks 321±115 lm; difference at 24 weeks was not statistically significant (P ¼ 0.9). A pigment epithelial detachment was present in 12 cases; height was reduced in 10 cases at 24 weeks. Persistent leakage on FA was seen in 13 out of 15 cases at 24 weeks. Conclusion Early results of treatment of RAP with intravitreal pegaptanib suggest some stabilizing effect on this normally progressive disease.

show abstract

Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation

Cited by 58 publications

References 22 publications

Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments

Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments

Late Stage III Retinal Angiomatous Proliferation with Retino-Choroidal Anastomosis do not Respond Well to Treatment with Ranibizumab (Lucentis®)

Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review

Contact Info

Product

Resources

About